Yesterday, CombiGene announced the signing of a production agreement with the Spanish gene therapy manufacturer Viralgen for the production of the drug candidate CG01. The choice of partner is based on the fact that Viralgen can manufacture the candidate on a large scale, which means both cost savings and faster development of CG01, a gene therapy developed for the treatment of patients with drug-resistant focal epilepsy.

Combigene. 189 likes · 9 talking about this. Biotechnology Company

On 15 May 2018, CombiGene announced that Horizon 2020 – EU’s Framework Programme for Research and Development – is investing EUR 3.36 million in CombiGene’s continued development and commerzialisation of the gene therapy project CG01, which is developed to treat drug-resistant focal epilepsy. Foundation for future commercial supply of CG01 secured with delivery of three Master Cell Banks Lund, Sweden and Keele, UK, 18th of August 2020:Cobra Biologics In 2021, CombiGene's epilepsy project CG01 will focus on the final preclinical studies. In parallel, the company will intensify preparations for studies in huma With the recruitment of Pernilla Fagergren, CombiGene strengthens the company further for the clinical studies in the epilepsy project CG01 | Placera BioStock: CombiGene gears up in epilepsy project Fri, Sep 04, 2020 08:55 CET. Yesterday, CombiGene announced the signing of a production agreement with the Spanish gene therapy manufacturer Viralgen for the production of the drug candidate CG01. CombiGene and Cobra Biologics sign agreement to secure GMP production of plasmids for production of CombiGene's gene therapy CG01 10th Sep 2020 Gene Therapy , CombiGene , plasmid dna , CG01 , epilepsy CombiGene and CGT Catapult collaboration completes development of quality control analytical assays for clinical production of CombiGene’s AAV-based gene therapy for the treatment of epilepsy Publicerad: 2020-09-15 (MFN) Combigene är ett forskningsbolag. Idag fokuserar bolaget på att utveckla nya behandlingar avsedda för olika neurologiska sjukdomar.

Cobra Biologics, an international CDMO for biologics and pharmaceuticals, and CombiGene AB (publ), a leading Nordic gene therapy company, today announced the successful production and delivery, by Cobra, of the first DNA plasmid required to produce CombiGene’s gene therapy drug candidate CG01, developed for the treatment of drugresistant (Svensk version nedan) Collaboration supports progression of Epilepsy Gene Therapy toward clinical trials. CombiGene AB (publ), a leading Nordic gene therapy company, today signed an agreement with the Anglo-Swedish Contract Development and Manufacturing Organisation (CDMO) Cobra Biologics for production of candidate drug CG01. Cobra Biologics, part of the Cognate BioServices family and CombiGene announced Cobra has successfully produced and supplied two further DNA plasmids for the production of CombiGene’s gene therapy drug candidate CG01, which is being developed for the treatment of drug-resistant focal epilepsy. CombiGene 's epilepsy project CG01 is now advancing to the final phase of the preclinical program.

On 15 May 2018, CombiGene announced that Horizon 2020 – EU’s Framework Programme for Research and Development – is investing EUR 3.36 million in CombiGene’s continued development and commerzialisation of the gene therapy project CG01, which is developed to treat drug-resistant focal epilepsy.

Tuesday the 15.th of May, late afternoon, CombiGene's CEO Jan Nilsson released the news that the EU framework programme for research and development, Horizon 2020, will invest 3.6 million euros in CombiGene's ongoing development and commercialization of their gene therapy project focusing on difficult-to-treat epilepsy in humans.

The purpose of International Epilepsy Day is for all the world’s epilepsy associations to jointly acknowledge and highlight the disease and its consequences. Last week, CombiGene reported that the company’s two warrants were exercised at 98.4 percent, which thus added just over SEK 25 million to the company.

Tuesday the 15.th of May, late afternoon, CombiGene's CEO Jan Nilsson released the news that the EU framework programme for research and development, Horizon 2020, will invest 3.6 million euros in CombiGene's ongoing development and commercialization of their gene therapy project focusing on difficult-to-treat epilepsy in humans.

Karin Agerman, Chief research and 2 dec. 2015 — Den New York-baserade affärsutvecklingskonsulten Lacerta Bio kommer att skriva och publicera en serie artiklar om epilepsi, genterapi och 26 nov. 2020 — Combigene är ett svenskt företag som nischar in sig på att effektivisera genterapi för bland annat epilepsi och lipodystrofi. Dagens Börs har fått 18 aug.

In 2021, CombiGene's epilepsy project CG01 will focus on the final preclinical studies.
Nordlander bygg sundsvall

Read the full interview with Jan 18 dec. 2015 — en kronisk sjukdom som exempelvis epilepsi med en engångsbehandling, berättar Bengt Westrin.

Today, CombiGene successfully completed the first large-scale production of its drug candidate CG01, which is being developed for the treatment of drug-resistant focal epilepsy. An agreement was also signed during the week with British Neurochase to optimise the injection strategy and maximise the safety and effect of CG01, which is to be injected directly into human brain tissue.

Human expression study confirms that human brain cells can express CombiGene’s candidate drug, CG01. 2018 Yesterday, CombiGene announced the signing of a production agreement with the Spanish gene therapy manufacturer Viralgen for the production of the drug candidate CG01. On 15 May 2018, CombiGene announced that Horizon 2020 – EU’s Framework Programme for Research and Development – is investing EUR 3.36 million in CombiGene’s continued development and commerzialisation of the gene therapy project CG01, which is developed to treat drug-resistant focal epilepsy. CombiGene There are 50 million people in the world living with epilepsy, of which 81,000 lives in Sweden. The purpose of International Epilepsy Day is for all the world’s epilepsy associations to jointly acknowledge and highlight the disease and its consequences.